16,175 Shares in Axovant Sciences Ltd. (AXON) Acquired by Tocqueville Asset Management L.P.
Tocqueville Asset Management L.P. bought a new position in shares of Axovant Sciences Ltd. (NYSE:AXON) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,175 shares of the biotechnology company’s stock, valued at approximately $375,000.
Several other large investors have also recently modified their holdings of AXON. Primecap Management Co. CA boosted its stake in shares of Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock worth $43,011,000 after buying an additional 2,159,428 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock worth $3,124,000 after buying an additional 197,600 shares during the last quarter. Norges Bank purchased a new stake in shares of Axovant Sciences during the fourth quarter worth about $508,000. Nationwide Fund Advisors boosted its stake in shares of Axovant Sciences by 70.9% in the first quarter. Nationwide Fund Advisors now owns 83,543 shares of the biotechnology company’s stock worth $1,248,000 after buying an additional 34,654 shares during the last quarter. Finally, C WorldWide Group Holding A S boosted its stake in shares of Axovant Sciences by 20.0% in the second quarter. C WorldWide Group Holding A S now owns 131,500 shares of the biotechnology company’s stock worth $3,049,000 after buying an additional 21,900 shares during the last quarter.
Axovant Sciences Ltd. (NYSE AXON) opened at 19.74 on Thursday. The firm’s market cap is $2.12 billion. The company has a 50-day moving average of $22.21 and a 200-day moving average of $19.71. Axovant Sciences Ltd. has a 52 week low of $11.01 and a 52 week high of $26.49.
Axovant Sciences (NYSE:AXON) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. Equities research analysts forecast that Axovant Sciences Ltd. will post ($2.41) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/31/16175-shares-in-axovant-sciences-ltd-axon-acquired-by-tocqueville-asset-management-l-p.html.
A number of equities research analysts have recently issued reports on AXON shares. Cowen and Company reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Axovant Sciences in a report on Wednesday, June 21st. Zacks Investment Research cut shares of Axovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. CIBC upped their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, June 14th. BidaskClub raised shares of Axovant Sciences from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Finally, Jefferies Group LLC started coverage on shares of Axovant Sciences in a report on Monday, July 10th. They issued a “buy” rating and a $40.00 target price on the stock. Three investment analysts have rated the stock with a sell rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $27.75.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.